Uthever® NMN and NAD+: What the Clinical Study Actually Found
If you've spent any time shopping for NMN, you've probably noticed that a lot of brands use the word "clinical" pretty loosely. A study in mice becomes "clinically backed." A cell culture experiment turns into "proven." It's easy to see why people get skeptical of the whole category.
So let's be precise about what's actually behind Uthever® NMN, the ingredient in ProHealth's NMN Pro 1000™. There is a real, published, peer-reviewed human trial here, and we'll walk through exactly what it did, and didn't, find.
What NAD+ Actually Does
NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme every cell in the body relies on. It's involved in converting food into usable energy and plays a role in hundreds of metabolic reactions that keep cells running. Whether NAD+ reliably declines with age is actually less settled than most headlines suggest. Research measuring NAD+ in specific tissues, such as muscle, has reported age-related decline (Janssens et al., 2022). But a May 2026 study in Nature Metabolism (Trętowicz et al.) found that whole-blood NAD+ specifically does not reliably decline with age or respond to lifestyle interventions, the same measurement used in most human NMN and NR trials, including the one below. It's an active research question, not a settled fact, and worth knowing that going in. NMN, or nicotinamide mononucleotide, is one of the more direct precursors the body can convert into NAD+.
What Makes Uthever® NMN Different From Other NMN Supplements
NMN by itself isn't unique to one brand. Dozens of supplement companies sell some version of it. Uthever® is a specific, branded form of NMN, and it's the version ProHealth uses in NMN Pro 1000™. It's also the version behind the clinical trial below. One thing to flag upfront: this trial evaluated Uthever® specifically, so its findings shouldn't automatically be generalized to other forms or sources of NMN.
The Uthever® NMN Clinical Study: Design and Method
The trial, “A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever® (Uthever Supplement)...”, was published in Frontiers in Aging in May 2022 (DOI 10.3389/fragi.2022.851698). It was a multicentre, randomized, double-blind, placebo-controlled, parallel-group design, run across two clinical sites in India, enrolling adults between 40 and 65.
Seventy people were screened and 66 eligible participants were randomized. After unblinding, the researchers reported 31 participants in the NMN arm and 35 in the placebo arm; they then randomly selected 31 participants from each group for the efficacy analysis. Participants in the NMN group took 300 mg of Uthever® NMN daily, in two 150 mg capsules after breakfast, for 60 days.
Uthever® NMN Study Results: NAD+ Increase and Key Findings
At the 30-day mark, NAD+/NADH levels in the NMN group had risen 11.3%, while the placebo group showed no measurable change. By day 60, NAD+/NADH levels in the Uthever® NMN group had risen 38% from baseline, versus 14.3% in the placebo group. The larger increase in the NMN group is encouraging, although the difference between groups was not statistically significant.
A few secondary findings deserve a mention too, all with the same caveat: none of the between-group differences below reached statistical significance, so they’re worth reading as promising rather than conclusive. The Uthever® group covered more distance in the 6-minute walk test by day 60 than at baseline, a numerically greater improvement than placebo. Self-reported quality of life (measured with the SF-36 questionnaire) followed a similar pattern: scores rose 6.5% from baseline by day 60 in the NMN group versus 3.4% in the placebo group. HOMA-IR, a measure of insulin resistance, stayed nearly flat in the Uthever® group (1.78 to 1.79) while climbing numerically in the placebo group (1.83 to 2.39; p = 0.18) - this one deserves extra caution, since insulin resistance connects to metabolic health more broadly. On safety, the study reported no specific adverse effects tied to the supplement itself; one case of dyslipidemia occurred in each group, NMN and placebo alike. Because the study was small and short-term, it cannot establish long-term safety. cannot establish long-term safety.
Limitations of the Uthever® NMN Study
This is the part that's easy to skip past, and exactly the part that shouldn't be.
First, this is one trial with about 60 participants over 60 days. It had several strong design features: it was randomized, double-blind, placebo-controlled, multicenter, and conducted in humans. However, it was small and short-term, and the between-group differences reported for the outcomes discussed above were not statistically significant.
How Uthever® NMN Fits Into NMN Pro 1000™'s 1,000 mg Dose
One nuance to flag upfront: Uthever® itself has been evaluated in a human randomized controlled trial at 300 mg per day. NMN Pro 1000™ contains the same branded ingredient but provides a different amount per serving (1,000 mg), and this study did not test NMN Pro 1000™ at its 1,000 mg serving. NMN Pro 1000™ is third-party tested and manufactured in an FDA-registered, GMP-certified facility, with certificates of analysis available on request.
Uthever® NMN: Common Questions
Is Uthever® NMN the same thing as NMN Pro 1000™?
No. Uthever® is the ingredient ProHealth uses inside the NMN Pro 1000™ formula, not a separate product on its own.
How does a 38% increase compare to other NAD+ ingredients?
It's hard to say definitively. Different studies use different measurement methods, doses, and durations, so a clean side-by-side comparison isn't really possible from published data alone. [Once live, link to the Month 2 NMN vs NR article for a closer look at how these two ingredients compare in the research so far.]
Does this mean NMN reverses aging?
No, and precision matters here. The study measured a rise in NAD+/NADH levels, along with a few secondary markers like self-reported quality of life and walk-test performance. It did not measure or claim anything about biological age. Any claim along those lines would need its own, separate substantiation.
References:
Huang, H. (2022). A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults. Frontiers in Aging. DOI: 10.3389/fragi.2022.851698.
Trętowicz, M. M., et al. (2026). Whole-blood NAD+ levels do not reflect healthy ageing. Nature Metabolism.
Janssens, G. E., et al. (2022). Healthy aging is associated with higher NAD+ levels in skeletal muscle, but not in blood.